α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer

Zhenfu Han, Peter K.W. Harris, Partha Karmakar, Tommy Kim, Ben Y. Owusu, Scott A. Wildman, Lidija Klampfer, James W. Janetka

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Upregulation of the HGF and MSP growth-factor processing serine endopeptidases HGFA, matriptase and hepsin is correlated with increased metastasis in multiple tumor types driven by c-MET or RON kinase signaling. We rationally designed P1' α-ketobenzothiazole mechanism-based inhibitors of these proteases. Structure-activity studies are presented, which resulted in the identification of potent inhibitors with differential selectivity. The tetrapeptide inhibitors span the P1-P1' substrate cleavage site via a P1' amide linker off the benzothiazole, occupying the S3' pocket. Optimized inhibitors display sub-nanomolar enzyme inhibition against one, two, or all three of HGFA, matriptase, and hepsin. Several compounds also have good selectivity against the related trypsin-like proteases, thrombin and Factor Xa. Finally, we show that inhibitors block the fibroblast (HGF)-mediated migration of invasive DU145 prostate cancer cells. In addition to prostate cancer, breast, colon, lung, pancreas, gliomas, and multiple myeloma tumors all depend on HGF and MSP for tumor survival and progression. Therefore, these unique inhibitors have potential as new therapeutics for a diverse set of tumor types.

Original languageEnglish
Pages (from-to)585-599
Number of pages15
JournalChemMedChem
Volume11
Issue number6
DOIs
StatePublished - Mar 17 2016

Keywords

  • cancer
  • cell signaling
  • metastasis
  • serine protease inhibitors
  • solid-phase peptide synthesis
  • structure-based drug design

Fingerprint

Dive into the research topics of 'α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer'. Together they form a unique fingerprint.

Cite this